SSRIs significantly increase the risk of both serious and non-serious adverse events .
The potential small beneficial effects seem to be outweighed by harmful effects .
Background The evidence on selective serotonin reuptake inhibitors ( SSRIs ) for major depressive disorder is unclear .
Methods Our objective was to conduct a systematic review assessing the effects of SSRIs versus placebo , ‘ active ’ placebo , or no intervention in adult participants with major depressive disorder .
Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials
GSK372475 is a triple reuptake inhibitor with approximately equipotent inhibition of serotonin , norepinephrine , and dopamine transporters . Two r and omized , placebo- and active-controlled , double-blind studies examined the efficacy and safety of GSK372475 in out patients ( aged 18–64 years ) with a diagnosis of major depressive episode associated with major depressive disorder ( MDD ) . Patients were r and omized 1:1:1 to placebo , GSK372475 ( 1–2 mg/d ) , or active control ( Study 1 :  venlafaxine XR 150–225 mg/d ; Study 2 : paroxetine 20–30 mg/d ) .  GSK372475 did not significantly differ from placebo on any of the key efficacy endpoints ( six-item Bech scale , IDS-Clinician Rated , MADRS ) in either study . Both active controls demonstrated significant antidepressant activity compared with placebo on both primary and secondary endpoints . The most common adverse effects ( AEs ) with GSK372475  were dry mouth , headache , insomnia , and nausea . AEs were more frequent for GSK372475 versus placebo for sleep , anxiety-related , gastrointestinal , and tachycardia events . Increases in mean change from baseline in heart rate and sitting blood pressure were greater for GSK372475 than observed for either placebo or active control groups . Completion rates were lower for GSK372475 ( 49 % , 58 % ) compared with placebo ( 67 % , 74 % ) , venlafaxine XR ( 63 % ) , or paroxetine ( 77 % ) . GSK372475 was neither efficacious nor well tolerated in patients with MDD in two 10-week studies
SSRIs significantly increase the risk of both serious and non-serious adverse events .
The potential small beneficial effects seem to be outweighed by harmful effects .
Background The evidence on selective serotonin reuptake inhibitors ( SSRIs ) for major depressive disorder is unclear .
Methods Our objective was to conduct a systematic review assessing the effects of SSRIs versus placebo , ‘ active ’ placebo , or no intervention in adult participants with major depressive disorder .